174 related articles for article (PubMed ID: 37990064)
1. Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biology.
Reitsam NG; Grozdanov V; Löffler CML; Muti HS; Grosser B; Kather JN; Märkl B
Cancer Gene Ther; 2024 Feb; 31(2):207-216. PubMed ID: 37990064
[TBL] [Abstract][Full Text] [Related]
2. SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
Enke JS; Groß M; Grosser B; Sipos E; Steinestel J; Löhr P; Waidhauser J; Lapa C; Märkl B; Reitsam NG
BMC Cancer; 2024 Jan; 24(1):65. PubMed ID: 38216952
[TBL] [Abstract][Full Text] [Related]
3. Stroma AReactive Invasion Front Areas (SARIFA): a novel histopathologic biomarker in colorectal cancer patients and its association with the luminal tumour proportion.
Reitsam NG; Grosser B; Enke JS; Mueller W; Westwood A; West NP; Quirke P; Märkl B; Grabsch HI
Transl Oncol; 2024 Jun; 44():101913. PubMed ID: 38593584
[TBL] [Abstract][Full Text] [Related]
4. Stroma AReactive Invasion Front Areas (SARIFA) proves prognostic relevance in gastric carcinoma and is based on a tumor-adipocyte interaction indicating an altered immune response.
Grosser B; Heyer CM; Austgen J; Sipos E; Reitsam NG; Hauser A; VanSchoiack A; Kroeppler D; Vlasenko D; Probst A; Novotny A; Weichert W; Keller G; Schlesner M; Märkl B
Gastric Cancer; 2024 Jan; 27(1):72-85. PubMed ID: 37874427
[TBL] [Abstract][Full Text] [Related]
5. Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA).
Reitsam NG; Märkl B; Dintner S; Sipos E; Grochowski P; Grosser B; Sommer F; Eser S; Nerlinger P; Jordan F; Rank A; Löhr P; Waidhauser J
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765951
[TBL] [Abstract][Full Text] [Related]
6. Stroma AReactive Invasion Front Areas (SARIFA) - a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes.
Grosser B; Glückstein MI; Dhillon C; Schiele S; Dintner S; VanSchoiack A; Kroeppler D; Martin B; Probst A; Vlasenko D; Schenkirsch G; Märkl B
J Pathol; 2022 Jan; 256(1):71-82. PubMed ID: 34580877
[TBL] [Abstract][Full Text] [Related]
7. Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
Grosser B; Emmerson J; Reitsam NG; Cunningham D; Nankivell M; Langley RE; Allum WH; Trepel M; Märkl B; Grabsch HI
Br J Cancer; 2024 Feb; 130(3):457-466. PubMed ID: 38123705
[TBL] [Abstract][Full Text] [Related]
8. Stroma AReactive Invasion Front Areas (SARIFA)-A New Easily to Determine Biomarker in Colon Cancer-Results of a Retrospective Study.
Martin B; Grosser B; Kempkens L; Miller S; Bauer S; Dhillon C; Banner BM; Brendel EM; Sipos É; Vlasenko D; Schenkirsch G; Schiele S; Müller G; Märkl B
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638364
[TBL] [Abstract][Full Text] [Related]
9. Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation study.
Ulase D; Behrens HM; Röcken C
Virchows Arch; 2024 May; ():. PubMed ID: 38748262
[TBL] [Abstract][Full Text] [Related]
10. Spatially aware graph neural networks and cross-level molecular profile prediction in colon cancer histopathology: a retrospective multi-cohort study.
Ding K; Zhou M; Wang H; Zhang S; Metaxas DN
Lancet Digit Health; 2022 Nov; 4(11):e787-e795. PubMed ID: 36307192
[TBL] [Abstract][Full Text] [Related]
11. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.
Khan M; Loree JM; Advani SM; Ning J; Li W; Pereira AAL; Lam M; Raghav K; Morris VK; Broaddus R; Maru D; Overman MJ; Kopetz S
Clin Colorectal Cancer; 2018 Dec; 17(4):e699-e709. PubMed ID: 30205948
[TBL] [Abstract][Full Text] [Related]
14. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
15. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.
Dunne PD; O'Reilly PG; Coleman HG; Gray RT; Longley DB; Johnston PG; Salto-Tellez M; Lawler M; McArt DG
Oncotarget; 2016 Jun; 7(24):36632-36644. PubMed ID: 27153559
[TBL] [Abstract][Full Text] [Related]
16. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
[TBL] [Abstract][Full Text] [Related]
17. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer.
Chen MH; Chang SC; Lin PC; Yang SH; Lin CC; Lan YT; Lin HH; Lin CH; Lai JI; Liang WY; Lu ML; Yang MH; Chao Y
Oncologist; 2019 Dec; 24(12):1534-1542. PubMed ID: 31292272
[TBL] [Abstract][Full Text] [Related]
18. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
[TBL] [Abstract][Full Text] [Related]
19. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
20. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
